GlassScriptPhysician profile
Laura C Vance
NPI 1225050784
$4,601.15
in general payments reported to CMS, 2019-2025
37 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $77.56 · 2021: $27.03 · 2022: $476 · 2023: $1,311 · 2024: $852 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,546.47 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $588.09 | 2022-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $584.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $542.33 | 2019-2025 | |
| Lilly USA, LLC | $395.03 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $385.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $240.02 | 2019-2025 | Shingrix, Arexvy, Nucala |
| Eisai INC. | $190.23 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.55 | 2025 | Caplyta |
| Amgen INC. | $170.28 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $142.19 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Biohaven Pharmaceutical Holding Company LTD. | $107.52 | 2022 | |
| Abbott Laboratories | $96.63 | 2022-2025 | Freestyle Libre |
| Lundbeck LLC | $89.54 | 2024-2025 | Rexulti |
| Globus Medical, INC. | $75.96 | 2025 | Senza |
| Otsuka America Pharmaceutical, INC. | $74.57 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.